You are here: Home » PTI Stories » National » News
Business Standard

Cipla arm secures marketing rights for cancer drug in US

Press Trust of India  |  New Delhi 

Drug today said its subsidiary has secured rights from Hyderabad-based Laboratories to market and distribute treatment drug in the US market.

USA, Inc, a subsidiary of the company will be marketing the drug in strengths of 150 and 500 mg tablets.

The company's product is generic equivalent of Genentech's Xeloda.

tablets are indicated in patients with and for the treatment of patients with after failure of prior anthracycline-containing

As per IQVIA (IMS Health) dat, Xeloda and its generic equivalents had sales of around USD 178 million in the US for 12-month period ending June 2018.

Shares of today ended 0.27 per cent up at Rs 620.90 on the

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Fri, August 10 2018. 21:10 IST